护肝解纤汤治疗大鼠肝纤维化的作用观察

目的 观察护肝解纤汤治疗大鼠肝纤维化的效果及其与抗过氧化损伤的关系.方法 以四氯化碳腹腔内注射法建立大鼠肝纤维化模型,造模成功后给予自拟的含低、中、高剂量姜黄的护肝解纤汤,以小柴胡汤治疗组和复方鳖甲软肝片治疗组为阳性对照.12周后取血并处死大鼠,用放射免疫法检测肝纤维化指标.留取肝左叶同一部位新鲜肝组织,部分行HE、Masson染色,根据SSS计分系统评估肝纤维化程度;部分制成匀浆,离心后留取上清,检测超氧化物歧化酶(SOD)、丙二醛(MDA)含量.结果 护肝解纤汤能降低肝纤维化模型大鼠升高的肝纤维化指标清Ⅲ型前胶原(PC-Ⅲ)、层黏连蛋白(LN)、透明质酸(HA)含量,降低病理评分,其中以低剂量姜黄组效果明显(P<0.05).护肝解纤汤可升高肝组织中SOD,降低MDA,其中以低剂量姜黄组效果明显(P<0.05).结论 护肝解纤汤能改善大鼠肝纤维化,其抗肝纤维化作用可能与保护肝细胞膜及抗过氧化损伤有关.     

护肝解纤汤治疗大鼠肝纤维化的作用观察

Objective To observe therapeutic effects of HuGanJieXian decoction on rats hepatic fibrosis induced by tetrachloride. Methods Rat models of hepatic fibrosis were constructed by intraperitoneal injection of tetrachloride.HuGanJieXian decoction composed of low, middle, and high dose curcumin were given to these rats respectively at the same time. Sho-saiko-to compound treatment group and Fufangbiejiarangan Tablets treatment group were made as positive control groups. After twelve weeks, all rats were executed. Serum samples were kept for measuring serum levels of PC-Ⅲ, LN, and HA. Left livers were extirpated for pathologic examination including H.E and Masson stainings. Grade of hepatic fibrosis were evaluated according to SSS system. The levels of superoxide dismutase (SOD) and malondialdehyde (MDA) of supematant centrifugated from hepatic tissue homogenate were detected. Results Serum levels of PC-Ⅲ, LN, and HA were depressed obviously in decoction groups compared with those of fibrotic group (P<0.05) , especially in the low-dose curcumin group.HuGanJieXian Decoction could increase the level of SOD and decrease the level of MDA (P<0.05) , especially in the low-dose curcumin group. Staining of H. E and Masson showed that degrees of hepatic fibrosis in decoction groups were improved obviously compared with that of the fibrotic group. Conclusion HuGanJieXian Decoction can improve rat hepatic fibrosis, the mechanism of this effect may be associated with protecting hepatic cell membrane and anti- peroxidative damage.     

益生菌治疗乙肝后肝硬化失代偿期的临床应用

目的探讨益生菌辅助治疗对乙肝后肝硬化失代偿期患者肝功能和肠道黏膜通透性的影响。方法选取2015年12月—2018年6月我院收治的110例乙肝后肝硬化失代偿期患者,采用随机数字表法分为观察组(n=55)和对照组(n=55)。对照组患者接受常规治疗,观察组患者在常规治疗的基础上给予益生菌辅助治疗。观察两组患者治疗前后的肝功能和肠道黏膜通透性变化。结果(1)治疗后,两组患者的(ALT)、谷草转氨酶(AST)和总胆红素(TBIL)水平均显著降低,白蛋白(ALB)水平显著升高,组间比较差异有统计学意义(P 0.05)。(2)治疗后,两组患者的乳果糖(LAC)、甘露醇(MAN)和LAC/MAN均显著降低,组间比较差异有统计学意义(P 0.05)。结论益生菌辅助治疗能显著改善乙肝后肝硬化失代偿期患者肝功能和肠道黏膜通透性,效果显著。     

护肝解纤汤对肝纤维化大鼠血清学指标的影响

目的 观察护肝解纤汤对肝纤维化大鼠肝功能、肝纤维化指标的影响,探讨其对肝纤维化的治疗作用.方法 以四氯化碳腹腔内注射的方法建立大鼠肝纤维化模型,造模后施以由低、中、高剂量姜黄及其他中药组成的护肝解纤汤,以小柴胡汤和复方鳖甲软肝片为阳性对照.12周后最大量取血并处死大鼠.检测血清肝功能、Ⅲ型前胶原(PC-Ⅲ)、透明质酸(HA)、层粘连蛋白(LN)含量.结果 模型组大鼠血清中ALT、AST含量升高,而ALB含量有所降低,各药物处理组ALT、AST较模型组降低,ALB较模型组升高,以复方鳖甲软肝片组更明显(P<0.05).模型组大鼠肝纤维化指标较正常组明显升高,各药物处理组纤维化指标均较模型组降低,尤以低姜黄组和复方鳖甲软肝片组降低明显(P<0.05).结论 护肝解纤汤可改善肝纤维化大鼠肝功能,显著降低肝纤维化指标,具有治疗肝纤维化的作用.     

护肝解纤汤治疗肝纤维化及其作用机制的初步研究

目的 观察护肝解纤汤治疗大鼠肝纤维化效果及有关细胞因子的变化,初步探讨护肝解纤汤的作用机制.方法 100只雄性SD大鼠随机分组后,以四氯化碳腹腔内注射的方法建立大鼠肝纤维化模型,造模后施以由低、中、高剂量姜黄等组成的护肝解纤汤,以小柴胡汤和复方鳖甲软肝片为阳性对照.12周后处死大鼠,留取肝左叶同一部位新鲜肝组织,行苏木素-伊红、Masson染色,免疫组织化学染色检测肝组织Ⅰ、Ⅲ型胶原,转化生长因子β1(TGF β1)、血小板衍生长因子(PDGF-BB)的变化.多组数据间的比较采用SPSS12.0统计软件进行单因素方差分析.结果 护肝解纤汤能降低病理评分,改善肝纤维化病理损伤,抑制Ⅰ、Ⅲ型胶原合成并促使其降解,降低炎症因子TGF β1、PDGF-BB在肝组织的表达,正常组、模型对照组、低姜黄组、中姜黄组、高姜黄组、小柴胡汤组、复方鳖甲组肝组织TGF阳性面积百分比分别为7.56%±2.18%、29.25%±7.84%、13.54%±4.15%、21.82%±6.64%、20.06%±7.14%、13.78%±4.35%、12.75%±3.98%,P<0.05;PDGF-BB阳性百分比分别为1.68%±0.41%、11.70%±2.28%、3.65%±0.76%、5.24%±1.04%、6.37%±1.12%、4.16%±0.61%、3.38%±0.56%,P<0.05.上述作用以低姜黄组效果明显.结论 护肝解纤汤可改善大鼠肝纤维化的病理改变,降低Ⅰ型胶原、Ⅲ型胶原合成、减少PDGF-BB,TGF β1表达可能是其相关作用机制.     

复方中药1号对大鼠肝纤维化疗效观察

目的:观察自拟复方中药1号对大鼠肝纤维化的疗效.方法:135只SD大鼠随机分为正常对照组、阴性对照组、模型组、自拟复方中药1号各剂量组、小柴胡汤组及复方鳖甲软肝片组.以四氯化碳腹腔注射8 w建立大鼠肝纤维化模型,第9周予以自拟复方中药1号等处理6 w,共14 w后处死大鼠,检测血清肝功能指标、Ⅲ型前胶原(PC-Ⅲ)、透明质酸(HA)、层粘连蛋白(LN)含量,肝组织行HE及Masson染色,光镜下观察病理改变,并按肝纤维化半定量计分系统进行评分.结果:与模型组比较,自拟复方中药方剂能显著降低大鼠血清ALT、AST、PC-Ⅲ、HA、LN水平(P＜0.01),病理切片显示肝组织纤维化程度明显改善.结论:自拟复方中药1号可改善肝功能、肝纤维化指标及肝脏组织病理学,具有治疗肝纤维化的作用.     

护肝解纤汤治疗大鼠肝纤维化的作用观察

Objective To observe therapeutic effects of HuGanJieXian decoction on rats hepatic fibrosis induced by tetrachloride. Methods Rat models of hepatic fibrosis were constructed by intraperitoneal injection of tetrachloride.HuGanJieXian decoction composed of low, middle, and high dose curcumin were given to these rats respectively at the same time. Sho-saiko-to compound treatment group and Fufangbiejiarangan Tablets treatment group were made as positive control groups. After twelve weeks, all rats were executed. Serum samples were kept for measuring serum levels of PC-Ⅲ, LN, and HA. Left livers were extirpated for pathologic examination including H.E and Masson stainings. Grade of hepatic fibrosis were evaluated according to SSS system. The levels of superoxide dismutase (SOD) and malondialdehyde (MDA) of supematant centrifugated from hepatic tissue homogenate were detected. Results Serum levels of PC-Ⅲ, LN, and HA were depressed obviously in decoction groups compared with those of fibrotic group (P<0.05) , especially in the low-dose curcumin group.HuGanJieXian Decoction could increase the level of SOD and decrease the level of MDA (P<0.05) , especially in the low-dose curcumin group. Staining of H. E and Masson showed that degrees of hepatic fibrosis in decoction groups were improved obviously compared with that of the fibrotic group. Conclusion HuGanJieXian Decoction can improve rat hepatic fibrosis, the mechanism of this effect may be associated with protecting hepatic cell membrane and anti- peroxidative damage.     

硝苯地平与拉贝洛尔合用对妊娠期高血压患者血浆BNP的影响

目的观察硝苯地平与拉贝洛尔合用治疗妊娠期高血压时,患者孕期血浆BNP的变化,探讨联合用药治疗妊娠高血压的最佳组合。方法选取石家庄市妇幼保健院产科于2018年5月~2019年2月就诊的妊娠期高血压患者,按照研究对象入组的顺序编号,随机将64例患者分为观察组32例和对照组32例,其中观察组给以硝苯地平和拉贝洛尔(均口服)联合治疗,而对照组给以硝苯地平和硫酸镁联合治疗,对比观察组和对照组治疗过程中血浆BNP变化情况,对治疗期间数据计算出t数值分析对比。结果观察组与对照组进行比较,观察组的血压稳定性明显优于对照组,差异有统计学意义,P<0.05。结论联合使用硝苯地平和拉贝洛尔(均口服)时,患者血浆BNP处于稳定水平,比硝苯地平与硫酸镁联合治疗时具有更好的效果,提示硝苯地平联合拉贝洛尔口服治疗妊娠期高血压实践效果可靠,稳定性好,值得临床推广。     

急性心肌梗死患者行急诊冠脉介入手术术中并发电风暴的抢救与护理分析

目的探讨急性心肌梗死行急诊冠脉介入手术术中并发电风暴的抢救与护理。方法回顾性分析9例急性心肌梗死行急诊冠脉介入手术中发生电风暴患者的临床资料,均予急救等处理,并全面加强护理,观察抢救后预后。结果 9例患者发生电风暴时间平均为(23.1±1.8)h,其中2例在6 h内出现,3例在术后6~12 h出现,2例12~24 h出现,1例24~48 h出现,1例48 h以后出现。电风暴持续时间平均(104.2±81.4)min;电击次数平均(9.8±5.7)次。经过一系列抢救护理后,24 h成功率为77.78%,2周内存活率为55.56%,1年内存活率为44.44%,24 h内死亡因频繁室颤,2周内死亡因心力衰竭,1年内死亡因术后并发症如心脏骤停等。结论急性心肌梗死患者行急诊冠脉介入手术术中并发电风暴经全面抢救和护理后,预后较满意。